please find enclosed outcome of the Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vivo Bio Tech Ltd reported audited financial results for FY2026. Standalone revenue grew 12.6% to Rs. 5,256.84 Lakhs from Rs. 4,667.25 Lakhs in FY2025. However, the company posted a net loss of Rs. 193.61 Lakhs (standalone) compared to a net profit of Rs. 757.07 Lakhs in FY2025. Q4 standalone net loss was Rs. 543.69 Lakhs. The sharp decline in profitability was partly due to a deferred tax liability change of Rs. 696.95 Lakhs and prior period items of Rs. 60.45 Lakhs. The board also approved re-appointment of Whole-time Director Mr. Kalyan Ram Mangipudi for 5 years, material related party transactions, and appointed an advisor for a proposed scheme of arrangement/amalgamation.
Despite revenue growth, the company turned loss-making in FY2026 due to deferred tax charges and other items, which may concern investors. The auditors issued an unmodified opinion but flagged unpaid statutory dues worth Rs. 419.29 Lakhs as an emphasis of matter.